个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Phase II Trial of X-396 (Ensartinib) for Chinese Patients with ALK (+) NoneSmall-Cell Lung Cancer Who Progressed on Crizotinib

| 认领 | 导出 | |

文献详情

资源类型：
作者：
Zhang, L.[1] ; Li, J.[2,3] ; Zhong, W.[4] ; Hu, Y.[5] ; Liu, X.[6] ; Wang, Z.[7] ; Zhao, Y.[8] ; Feng, J.[9] ; Zhou, J.[10] ; Zhang, Y.[1,2,3,4,5,6,7,8,9,10,11,12,13] ; Fan, Y.[11] ; Wu, G.[12] ; Tan, F.[13] ; Ding, L.[13] ;
机构： [1]Sun Yat Sen Univ, Med Oncol, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [2]Chinese Acad Med Sci, Med Oncol, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China; [3]Peking Union Med Coll, Beijing, Peoples R China; [4]Peking Union Med Coll Hosp, Beijing, Peoples R China; [5]Chinese Peoples Liberat Army Gen Hosp, Dept Med Oncol, Beijing, Peoples R China; [6]Acad Mil Med Sci, Canc Ctr, Dept Pulm Oncol, Hosp 307, Beijing, Peoples R China; [7]Shandong Prov Tumor Hosp, Jinan, Shandong, Peoples R China; [8]Henan Canc Hosp, Zhengzhou, Henan, Peoples R China; [9]Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China; [10]Zhejiang Univ, Resp Dis, Affiliated Hosp 1, Coll Med, Hangzhou, Zhejiang, Peoples R China; [11]Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China; [12]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China; [13]Betta Pharmaceut Co Ltd, Hangzhou, Zhejiang, Peoples R China
出处：
DOI： 10.1016/j.jtho.2017.11.016
ISSN：

关键词： crizotinib X-396 (ensartinib) ALK-rearranged non-small-cell lung cancer

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2017]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学 2 区 呼吸系统
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
第一作者：
第一作者机构： [1]Sun Yat Sen Univ, Med Oncol, Canc Ctr, Guangzhou, Guangdong, Peoples R China;
推荐引用方式(GB/T 7714)：
Zhang L.,Li J.,Zhong W.,et al.Phase II Trial of X-396 (Ensartinib) for Chinese Patients with ALK (+) NoneSmall-Cell Lung Cancer Who Progressed on Crizotinib[J].JOURNAL OF THORACIC ONCOLOGY.2017,12(11):S2398-S2398.doi:10.1016/j.jtho.2017.11.016.
APA：
Zhang, L.,Li, J.,Zhong, W.,Hu, Y.,Liu, X....&Ding, L..(2017).Phase II Trial of X-396 (Ensartinib) for Chinese Patients with ALK (+) NoneSmall-Cell Lung Cancer Who Progressed on Crizotinib.JOURNAL OF THORACIC ONCOLOGY,12,(11)
MLA：
Zhang, L.,et al."Phase II Trial of X-396 (Ensartinib) for Chinese Patients with ALK (+) NoneSmall-Cell Lung Cancer Who Progressed on Crizotinib".JOURNAL OF THORACIC ONCOLOGY 12..11(2017):S2398-S2398

相关文献

[1]Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer [2]First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK1) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis [3]Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. [4]Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma [5]Clinical Benefit of Continuing Crizotinib Therapy after Initial Disease Progression in Chinese Patients with Advanced ALK -Rearranged NSCLC [6]Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+NSCLC [7]Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report. [8]比较Crizotinib与培美曲塞/顺铂或培美曲塞/卡铂治疗 [9]BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-rearranged NSCLC: a Case Report. [10]Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号